GlassScriptPhysician profile
Hunter W Jacques
NPI 1326529041
$2,022.08
in general payments reported to CMS, 2019-2025
18 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $205 · 2024: $774 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,022.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.23 | 2023-2025 | |
| Ardelyx, INC. | $341.71 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $218.97 | 2023-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $185.95 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $161.20 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $155.36 | 2024 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $96.91 | 2024-2025 | Tremfya, Stelara |
| Celltrion USA INC. | $84.19 | 2025 | Vegzelma |
| Intercept Pharmaceuticals, INC. | $63.07 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.82 | 2025 | Entyvio |
| Genzyme Corporation | $60.11 | 2025 | |
| Merck Sharp & Dohme LLC | $46.17 | 2023-2024 | Dificid |
| Lilly USA, LLC | $39.91 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $30.80 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $26.61 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $21.31 | 2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $16.29 | 2024 | |
| Braintree Laboratories, INC. | $14.47 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Jacques listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.